General Atlantic-backed Centessa targets $1.7 bln valuation in U.S. IPO

Centessa Pharmaceuticals Plc, the newly formed biopharma company backed by private equity firm General Atlantic, said on Monday it was aiming for a valuation of up to $1.7 billion in its initial public offering in the United States.